What Would You Do in the Event of Contamination?- An Interview with Lada Laenen

Add bookmark

What Would You Do in the Event of Contamination?- An Interview with Lada Laenen

Add bookmark

In 2008 and 2009, Genzyme sites were affected by vesivirus infection. This shut down two sites for decontamination. In this candid interview, Lada Laenen, Managing Principal Scientist, Head, Cell Culture and Microbiology, Genzyme, a Sanofi Company, discusses how this affected Genzyme.  She explains what they have changed to avoid this happening again. Dr. Laenen also describes the company's creation of an 'organisms of concern' list, ensuring quality in raw materials and what's holding back the use of new technologies for pathogen detection.

[inlinead]


Upcoming Events

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

September 9 - 10, 2026

Steigenberger Airport Hotel Berlin, Deutschland

DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

Pharmaceutical Launch Excellence Summit US

September 30 - October 1 2026

Hyatt Regency Boston Harbor, Boston, US

Pharmaceutical Launch Excellence Summit US

SmartLab Exchange Europe

22 - 23 February 2027

Leonardo Royal Hotel Amsterdam, Netherlands

SmartLab Exchange Europe

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended